Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for Summit Therapeutics (SMMT) over the last 2 years, with Jun 2025 value amounting to $150.8 million.

  • Summit Therapeutics' Change in Acquisitions & Divestments rose 115.45% to $150.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $618.3 million, marking a year-over-year increase of 75.24%. This contributed to the annual value of $489.8 million for FY2024, which is 135.31% up from last year.
  • Latest data reveals that Summit Therapeutics reported Change in Acquisitions & Divestments of $150.8 million as of Q2 2025, which was down 6.06% from $160.5 million recorded in Q1 2025.
  • Summit Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $233.0 million during Q4 2024, with a 5-year trough of $38.2 million in Q2 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $112.1 million, with a median of $109.4 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Summit Therapeutics' Change in Acquisitions & Divestments was 284.66% (2024), while the steepest drop was 32.37% (2024).
  • Over the past 3 years, Summit Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $60.6 million in 2023, then spiked by 284.66% to $233.0 million in 2024, then soared by 115.45% to $150.8 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $150.8 million for Q2 2025, versus $160.5 million for Q1 2025 and $233.0 million for Q4 2024.